SCHEMBL30278461

SCHEMBL30278461

O=[N+]([O-])c1ccc2oc(=S)[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 3/20 1.00
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 3/20 0.49
KDM4E B2RXH2 2/20 0.49
GAA P10253 2/20 0.49
GRIA1 P42261 1/20 0.49
GRIA2 P42262 1/20 0.49
GRIA3 P42263 1/20 0.49
GRIA4 P48058 1/20 0.49
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
ALDH1A1 P00352 4/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP3A4 P08684 2/20 0.46
NAMPT P43490 1/20 0.46
XDH P47989 1/20 0.46
PARP1 P09874 1/20 0.44
MPI P34949 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2074264 1.00 PSMB8 (1.00) PSMB8MEN1KMT2AMAPTKDM4E
SCHEMBL30683873 0.87 PSMB8 (0.77) PSMB8MEN1KMT2AMAPTKDM4E
SCHEMBL224438 0.81 PSMB8 (0.69) PSMB8GRIA1GRIA2GRIA3GRIA4
SCHEMBL31187650 0.81 PSMB8 (0.69) PSMB8GRIA1GRIA2GRIA3GRIA4
SCHEMBL12716526 0.72 KDM4E (0.82) PSMB8MEN1KMT2AMAPTKDM4E
SCHEMBL3280475 0.72 GRIA1 (0.70) PSMB8MEN1KMT2AMAPTGRIA1
SCHEMBL31349397 0.71 PSMB8 (0.55) PSMB8ALDH1A1CYP3A4LMNA
SCHEMBL10897160 0.71 PSMB8 (0.63) PSMB8MEN1KMT2AMAPTKDM4E
SCHEMBL11102221 0.70 ALDH1A1 (0.63) PSMB8MEN1KMT2AMAPTKDM4E
SCHEMBL539847 0.69 PSMB8 (0.72) PSMB8MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof ENANTA PHARM INC (US) 2025-12-11 US disclosed
EP-4387603-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2024-06-26 EP disclosed
CN-118103038-A 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof 英安塔制药有限公司 2024-05-28 CN disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof HSD17B1, HSD17B13, HSD17B3 PSMB8 2386/4885MEN1 3138/4885KMT2A 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.